Assetmark Inc. Has $96.92 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Assetmark Inc. cut its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,653,112 shares of the biopharmaceutical company's stock after selling 46,151 shares during the quarter. Assetmark Inc. owned about 0.06% of Pfizer worth $96,917,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter worth $28,000. Gladius Capital Management LP lifted its holdings in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 38,015 shares during the period. Noble Wealth Management PBC bought a new position in Pfizer during the fourth quarter valued at about $31,000. Finally, Sierra Ocean LLC acquired a new position in Pfizer during the fourth quarter worth about $34,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Stock Up 0.7 %

Shares of PFE stock traded up $0.18 during trading on Wednesday, hitting $25.93. 37,049,759 shares of the company were exchanged, compared to its average volume of 39,279,996. The business's 50-day simple moving average is $26.31 and its 200 day simple moving average is $27.27. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market capitalization of $146.93 billion, a price-to-earnings ratio of 18.39, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. The company's revenue for the quarter was up 24.7% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.63%. Pfizer's payout ratio is presently 121.99%.

Analyst Ratings Changes

Several research firms have recently weighed in on PFE. Guggenheim restated a "buy" rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Finally, Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.